Skip to main content
Livermore
Livermore
ZHEN

Vanguard Group Inc

SEC CIK
0000102909
Latest filing
Jan 29, 2026

ELVN holding history

Enliven Therapeutics, Inc. in every 13F filed by Vanguard Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ELVN overviewAll 13F holders of ELVNFull Q4 2025 holdings

Shares (Q4 2025)
2,801,665
Value
$43.1M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of ELVN by Vanguard Group Inc, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20252,801,665$43.1M<0.1%+248,651+9.7%AddedHolders
Q3 20252,553,014$52.3M<0.1%+142,378+5.9%AddedHolders
Q2 20252,410,636$48.4M<0.1%+438,397+22.2%AddedHolders
Q1 20251,972,239$38.8M<0.1%−3,416−0.2%ReducedHolders
Q4 20241,975,655$44.5M<0.1%+55,283+2.9%AddedHolders
Q3 20241,920,372$49.0M<0.1%+98,912+5.4%AddedHolders
Q2 20241,821,460$42.6M<0.1%+638,194+53.9%AddedHolders
Q1 20241,183,266$20.8M<0.1%−47,622−3.9%ReducedHolders
Q4 20231,230,888$17.0M<0.1%+79,071+6.9%AddedHolders
Q3 20231,151,817$15.7M<0.1%+9,313+0.8%AddedHolders
Q2 20231,142,504$23.3M<0.1%+990,590+652.1%AddedHolders
Q1 2023151,914$3.33M<0.1%−289,299−65.6%ReducedHolders
Q4 2022441,213$1.80M<0.1%+137,058+45.1%AddedHolders
Q3 2022304,155$693.0K<0.1%+38,468+14.5%AddedHolders
Q2 2022265,687$324.0K<0.1%00.0%UnchangedHolders
Q1 2022265,687$500.0K<0.1%−218,217−45.1%ReducedHolders
Q4 2021483,904$1.09M<0.1%−1,000−0.2%ReducedHolders
Q3 2021484,904$1.98M<0.1%+293,493+153.3%AddedHolders
Q2 2021191,411$1.51M<0.1%−38,698−16.8%ReducedHolders
Q1 2021230,109$1.94M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.